Anti-tuberculosis drug resistance in Ethiopia: systematic review

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):18-22. doi: 10.5588/ijtld.16.0286.

Abstract

Background: Resistance to anti-tuberculosis drugs threatens to undermine effective control of tuberculosis (TB). In areas with weak TB control and misuse of anti-tuberculosis drugs, hotspots of multidrug-resistant TB (MDR-TB) have appeared. The aim of this review is to determine the prevalence rate of any anti-tuberculosis drug resistance, monoresistance and MDR-TB in Ethiopia.

Methods: A systematic review of the literature on any resistance, monoresistance and MDR-TB was conducted.

Results: Of the total 468 articles found using electronic search, 14 met the eligibility criteria and were included in the review. The prevalence rate of any drug resistance, polyresistance and MDR-TB was respectively 6.7-72.9%, 0-54% and 0-46%. A higher rate of streptomycin monoresistance (1.5-20.4%) was observed.

Conclusion: The prevalence and distribution of drug-resistant TB remains a serious public health problem in Ethiopia. Rapid, advanced diagnostic tools should be introduced, along with strong treatment and follow-up strategies.

Publication types

  • Systematic Review

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Drug Resistance, Multiple, Bacterial
  • Ethambutol / therapeutic use
  • Ethiopia / epidemiology
  • Humans
  • Isoniazid / therapeutic use
  • Prevalence
  • Public Health
  • Pyrazinamide / therapeutic use
  • Rifampin / therapeutic use
  • Streptomycin / therapeutic use
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / epidemiology*

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin
  • Streptomycin